본문 바로가기

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
피인용
Web of Science 39Scopus 40
FWCI (Scopus)
0
JCR IF
JCR 2019 11.059
ISSN
1756-8722

저자

  1. Weisel, Katja제1저자교신저자Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf Hamburg Germany
  2. Spencer, Andrewgrid.267362.4 0000 0004 0432 5259 Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University Melbourne Australia
  3. Lentzsch, Suzannegrid.21729.3f 0000000419368729 Division of Hematology/Oncology, Columbia University New York, NY USA
  4. Avet-Loiseau, Hervégrid.414295.f 0000 0004 0638 3479 Unite de Genomique du Myelome, CHU Rangueil Toulouse France
  5. Mark, Tomer M.grid.430503.1 0000 0001 0703 675X Department of Medicine, University of Colorado Aurora, CO USA
  6. Spicka, Ivangrid.4491.8 0000 0004 1937 116X Clinical Department of Haematology, 1st Medical Department, Charles University in Prague Prague Czech Republic
  7. Masszi, Tamasgrid.11804.3c 0000 0001 0942 9821 László Hospital, 3rd Department of Internal Medicine, Semmelweis University Budapest Hungary
  8. Lauri, BirgittaDepartment of Hematology, Sunderbyn Hospital Luleå Sweden
  9. Levin, Mark-Davidgrid.413972.a 0000 0004 0396 792X Department of Internal Medicine, Albert Schweitzer Hospital Dordrecht The Netherlands
  10. Bosi, Albertogrid.8404.8 0000 0004 1757 2304 Department of Hematology, Careggi Hospital and University of Florence Firenze Italy
  11. Hungria, Vaniagrid.419432.9 0000 0000 8872 5006 Irmandade Da Santa Casa De Misericordia De Saõ Paulo Saõ Paulo Brazil
  12. Cavo, Michelegrid.6292.f 0000 0004 1757 1758 "Seràgnoli" Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna Bologna Italy
  13. Lee, Je-Junggrid.411602.0 0000 0004 0647 9534 Department of Hematology-Oncology, Chonnam National University Hwasun Hospital Hwasun, Jeollanamdo South Korea
  14. Nooka, Ajaygrid.189967.8 0000 0001 0941 6502 Winship Cancer Institute, Emory University Atlanta, GA USA
  15. Quach, Hanggrid.413105.2 0000 0000 8606 2560 University of Melbourne, St Vincent's Hospital Melbourne Australia
  16. Munder, Markusgrid.410607.4 University Medical Center of the Johannes Gutenberg University, Third Department of Medicine Mainz Germany
  17. Lee, Cindygrid.416075.1 0000 0004 0367 1221 Royal Adelaide Hospital North Terrace Adelaide Australia
  18. Barreto, Wolneygrid.11899.38 0000 0004 1937 0722 University of Saõ Paulo Ribeiraõ Preto Brazil
  19. Corradini, Paologrid.4708.b 0000 0004 1757 2822 Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan Milan Italy
  20. Min, Chang-Kigrid.414966.8 0000 0004 0647 5752 Seoul St. Mary's Hospital Seoul South Korea
  21. Chanan-Khan, Asher A.grid.417467.7 0000 0004 0443 9942 Mayo Clinic Florida Jacksonville, FL USA
  22. Horvath, Noemigrid.416075.1 0000 0004 0367 1221 Royal Adelaide Hospital North Terrace Adelaide Australia
  23. Capra, Marcelogrid.414871.f 0000 0004 0491 7596 Instituto do Cancer-Hospital Mae de Deus Porto Alegre Brazil
  24. Beksac, Meralgrid.7256.6 0000000109409118 Ankara University Ankara Turkey
  25. Ovilla, RobertoHospital Angeles Lomas Naucalpan de Juárez y alrededores Mexico
  26. Jo, Jae-Cheolgrid.412830.c 0000 0004 0647 7248 Ulsan University Hospital Ulsan South Korea
  27. 신호진grid.412588.2 0000 0000 8611 7824 Department of Internal Medicine, Pusan National University Hospital Busan South Korea
  28. Sonneveld, Pietergrid.5645.2 000000040459992X Erasmus MC Rotterdam The Netherlands
  29. Casneuf, Tinekegrid.419619.2 0000 0004 0623 0341 Janssen Research & Development, LLC Beerse Belgium
  30. Deangelis, Nikkigrid.419619.2 0000 0004 0623 0341 Janssen Research & Development, LLC Beerse Belgium
저자 34명 모두 보기

초록

Background: Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) alone and exhibited tolerability in patients with relapsed or refractory MM (RRMM). Methods: This subgroup analysis evaluated D-Vd versus Vd in CASTOR based on cytogenetic risk, determined using fluorescence in situ hybridization and/or karyotype testing performed locally. High-risk patients had t(4;14), t(14;16), and/or del17p abnormalities. Minimal residual disease (MRD; 10(-5)sensitivity threshold) was assessed via the clonoSEQ (R) assay V2.0. Of the 498 patients randomized, 40 (16%) in the D-Vd group and 35 (14%) in the Vd group were categorized as high risk. Results: After a median follow-up of 40.0 months, D-Vd prolonged median PFS versus Vd in patients with standard (16.6 vs 6.6 months; HR, 0.26; 95% CI, 0.19-0.37;P< 0.0001) and high (12.6 vs 6.2 months; HR, 0.41; 95% CI, 0.21-0.83;P= 0.0106) cytogenetic risk. D-Vd achieved deep responses, including higher rates of MRD negativity and sustained MRD negativity versus Vd, regardless of cytogenetic risk. The safety profile was consistent with the overall population of CASTOR. Conclusion: These updated data reinforce the effectiveness and tolerability of daratumumab-based regimens for RRMM, regardless of cytogenetic risk status.

키워드

Clinical trialsMultiple myelomaMyeloma therapyINTERGROUPE FRANCOPHONEANTIBODY DARATUMUMABSURVIVALABNORMALITIESCONSENSUS

식별자

Scopus EID
2-s2.0-85089769416
WoS UID
000566236600001